A composition for improving skin dullness, a pack liquid, and a method for preparing the same

Abstract

The present application relates to a kind of compositions for improving skin dullness, mask liquid and its preparation method, include the following components by mass fraction, 3-ortho-ethyl ascorbic acid flexible body, phenylethyl resorcinol, Moringa oleifera seed oil and Adansonia digitata seed oil.The flexible body system without phospholipid, without cholesterol, without sorbitan is used, 3-ortho-ethyl ascorbic acid is efficiently loaded, the average particle size of flexible body is 152.6-243.5nm, PDI<0.25, good stability, solve the oxidation discoloration problem of 3-ortho-ethyl ascorbic acid.3-ortho-ethyl ascorbic acid flexible body can increase the penetration of 3-ortho-ethyl ascorbic acid, improve the color change and stratification phenomenon of mask liquid water phase, increase its stability.The present application provides a kind of instant emulsification water-oil mask formula for improving skin dullness, instant emulsification water-oil mask liquid can significantly inhibit melanin synthesis, reduce lipofuscin deposition, inhibit the generation of oxidation byproduct ROS, also have significant soothing effect.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and in particular to a composition for improving dull skin, a facial mask liquid, and a method for preparing the same. Background Technology

[0002] Dull skin tone not only affects the evenness and radiance of facial appearance but is also closely related to consumers' perception of their own skin condition. From a visual aesthetic perspective, a bright and even skin tone is generally considered a sign of health, youth, and vitality, while dull skin tone easily gives the impression of fatigue and aging. From a dermatological perspective, the causes of dull skin tone are complex, with the core mechanism being an imbalance in skin pigment metabolism, mainly manifested as an abnormal increase in melanin content and its uneven distribution in the epidermis. Under normal physiological conditions, melanin synthesis and metabolism are in dynamic equilibrium. Melanin granules synthesized by melanocytes are transported to surrounding keratinocytes and gradually cleared away with the shedding of the stratum corneum, thus maintaining the consistency and brightness of skin tone. However, when this balance is disrupted, excessive melanin synthesis or impaired metabolic clearance will lead to its abnormal deposition in the epidermis, resulting in dull skin tone. Factors inducing melanin metabolic imbalance are multifaceted, with post-inflammatory hyperpigmentation being a common cause. Inflammatory mediators released during skin inflammation can stimulate increased melanocyte activity, leading to excessive local melanin deposition. Oxidative stress can also promote melanin synthesis through multiple pathways. When melanin is excessively deposited or unevenly distributed in the epidermis, it can manifest visually as uneven skin tone, localized pigmentation, and an overall dull and lackluster complexion, severely affecting the appearance of the skin.

[0003] However, current cosmetic solutions for dull skin tone still have several shortcomings. Traditional whitening cosmetics mostly focus on inhibiting melanin synthesis pathways, paying insufficient attention to dullness caused by lipofuscin accumulation, making it difficult to comprehensively address the dullness problem of aging skin. Existing liposome systems have limited encapsulation efficiency and transdermal permeability for water-soluble active ingredients, and their vesicle structures lack deformability at the skin barrier, affecting the actual delivery efficiency of water-soluble active ingredients. While some lipid-soluble whitening ingredients, such as phenylethyl resorcinol, have good melanin-inhibiting effects, they suffer from poor water solubility and photostability in formulations, making them difficult to fully dissolve and stabilize in conventional aqueous systems.

[0004] Therefore, developing a skincare product that can solve problems such as dull skin, improve skin brightness and evenness, while reducing production energy consumption and maximizing the activity of active ingredients has great application potential. Summary of the Invention

[0005] To address the shortcomings of existing technologies, the present invention aims to provide a composition, a facial mask liquid, and a method for preparing the same for improving dull skin. Based on the aforementioned research findings, the present invention is thus completed.

[0006] To achieve the above-mentioned technical objectives, the present invention provides the following technical solution:

[0007] In a first aspect, the present invention provides a composition for improving dull skin, comprising, by weight, the following components: 3-o-ethyl ascorbic acid flexible body, phenylethyl resorcinol, moringa seed oil and baobab seed oil.

[0008] The 3-o-ethyl ascorbic acid flexible body comprises the following components in the indicated mass fractions: 1-8 parts of 3-o-ethyl ascorbic acid, 1-18 parts of polyglycerol-2 isostearate, 1-18 parts of β-sitosterol, 1-10 parts of polyglycerol-10 oleate, and water to a total of 100 parts.

[0009] The mass ratio of polyglycerol-2 isostearate, β-sitosterol, and polyglycerol-10 oleate is (35~45):(35~45):(15~25);

[0010] Preferably, 3-5 parts of 3-o-ethyl ascorbic acid, 14-18 parts of polyglycerol-2 isostearate, 14-18 parts of β-sitosterol, and 6-10 parts of polyglycerol-10 oleate;

[0011] The mass ratio of polyglycerol-2 isostearate, β-sitosterol, and polyglycerol-10 oleate is 40:40:20.

[0012] A second aspect of the present invention provides a method for preparing a 3-o-ethylascorbic acid flexible body.

[0013] S1. Preparation of oil phase: Polyglycerol-2 isostearate, β-sitosterol and polyglycerol-10 oleate are placed in a closed reaction vessel, dissolved in an organic solvent, heated to 40–50°C under inert gas protection, and stirred until completely dissolved and mixed evenly to obtain the oil phase;

[0014] S2. Preparation of aqueous phase: Dissolve 3-o-ethyl ascorbic acid in deionized water that has been degassed under vacuum, and heat to 40–50 °C to obtain the aqueous phase;

[0015] S3. Thin film formation: The oil phase obtained in S1 is placed in a rotary evaporation flask and rotary evaporated until no liquid drops fall, forming a uniform thin film on the inner wall of the container;

[0016] S4. Thin film hydration: Add the aqueous phase obtained in S2 to the thin film obtained in S3, and perform rotational hydration under nitrogen protection to obtain a flexible coarse dispersion.

[0017] S5. Particle size homogenization: The coarse dispersion of the flexible material obtained in S4 is cooled to 10°C~20°C and subjected to high-pressure homogenization or high-pressure shear homogenization to obtain a flexible material with an average particle size of 150–250 nm and PDI < 0.25.

[0018] In S1, the inert gas is one of nitrogen, argon or carbon dioxide, preferably nitrogen;

[0019] Inert gas protection is used to maintain a slight positive pressure of nitrogen or nitrogen sealing, wherein the slight positive pressure is 0.01 MPa to 0.05 MPa;

[0020] The organic solvent is selected from one or more of chloroform, ethanol, methanol, and diethyl ether, preferably a chloroform-ethanol mixed solvent with a volume ratio of 2:1 to 4:1.

[0021] The amount of organic solvent used is 4-10 times the total mass of the oil phase, preferably 6 times;

[0022] In S2, the vacuum degree of the vacuum degassing process is -0.08 MPa to -0.10 MPa, and the degassing time is 10–20 min;

[0023] In S3, the rotary evaporation temperature is 40°C~50°C, the vacuum degree is -0.06 MPa~-0.08 MPa, and the rotation speed is 40 rpm~60 rpm;

[0024] In S4, the temperature for rotary hydration is 40°C to 50°C, the rotation speed is 30 rpm to 40 rpm, and the time is 30 min to 60 min.

[0025] In S5, the pressure of high-pressure homogenization is 600–1000 bar, the number of cycles is 3–5, the temperature of the homogenization process does not exceed 40°C, and the temperature control method is to cool the flexible coarse dispersion to 10~20°C in an ice water bath before entering the homogenizer, or to use segmented homogenization or circulating cooling.

[0026] The high-pressure shear homogenization speed is 10,000 rpm to 20,000 rpm, and the time is 5 min to 15 min; the homogenization process temperature does not exceed 40°C; the temperature control method is to cool the flexible coarse dispersion to 10 to 20°C in an ice water bath before entering the homogenizer, or to use segmented homogenization or circulating cooling.

[0027] A third aspect of the present invention also provides a facial mask liquid, comprising an aqueous phase and an oil phase, wherein the aqueous phase and the oil phase comprise, by mass parts, the following components:

[0028] The aqueous phase includes 1-20 parts of 3-o-ethyl ascorbic acid flexible body, 2-10 parts of polyol, 0.01-2 parts of rheology modifier, 0.01-0.1 parts of chelating agent, 0.01-1 parts of preservative, and water to make up to 100 parts.

[0029] The oil phase includes 0.1-5 parts of moringa seed oil, 0.1-15 parts of baobab seed oil, 0.1-0.5 parts of phenylethyl resorcinol, 0.1-8 parts of sorbitol polyether-30 tetraisostearate, and 0.1-6 parts of polyglycerol-6 didecanoate, with liquid oils added to bring the total to 100 parts.

[0030] Preferably, the aqueous phase comprises 5-10 parts of 3-o-ethyl ascorbic acid flexible body, 4-6 parts of polyol, 0.01-0.5 parts of rheology modifier, 0.01-0.05 parts of chelating agent, 0.5-1 parts of preservative, and water to make up to 100 parts.

[0031] The oil phase includes 2-3 parts moringa seed oil, 5-10 parts baobab seed oil, 0.1-0.5 parts phenylethyl resorcinol, 0.1-6 parts sorbitol polyether-30 tetraisostearate, 0.1-4 parts polyglycerol-6 didecanoate, and liquid oils to make up to 100 parts.

[0032] The mass ratio of the aqueous phase to the oil phase is (25–18):(1–10), preferably 25:3;

[0033] The mass ratio of sorbitol polyether-30 tetraisostearate to polyglycerol-6 didecanoate is 3:2.

[0034] Preferably, the polyol is any one or two of erythritol and xylitol;

[0035] The rheology modifier is one or more of xanthan gum, carbomer, hydroxyethyl cellulose, hydrolyzed sclerotium gum, and AVC;

[0036] The chelating agent is one or more of EDTA-2Na and EDTA-4Na;

[0037] The preservative is one or more of p-hydroxyacetophenone and 1,2-hexanediol;

[0038] The liquid oil is one or more of the following: dioctyl carbonate, caprylic / capric triglyceride, isohexadecane, isopropyl myristate, isononyl isononanoate, and triglyceride (ethylhexanoate).

[0039] A fifth aspect of the present invention provides a method for preparing a facial mask liquid, comprising the following steps:

[0040] S1: Aqueous phase preparation: Polyol, rheology modifier, chelating agent and water are mixed and heated to 75–85 °C, stirred until completely dissolved and mixed evenly; then cooled down, preservative and 3-o-ethyl ascorbic acid flexible body are added, stirred and mixed evenly to obtain the aqueous phase;

[0041] S2: Oil phase preparation:

[0042] (1) Heat the liquid oil to 40~45°C, add phenylethyl resorcinol, moringa seed oil and baobab seed oil, stir for 10–15 min until completely dissolved, and cool to room temperature;

[0043] (2) Add sorbitol polyether-30 tetraisostearate and polyglycerol-6 didecanoate to (1), stir and mix evenly to obtain the oil phase;

[0044] S3: Phase Emulsification: Cool the aqueous phase obtained from S1 to room temperature and mix it evenly with the oil phase obtained from S2 to obtain an instant emulsified water-oil facial mask liquid.

[0045] Preferably, in step S1, the temperature is cooled to 65-75°C, a preservative is added, the temperature is further cooled to 35-45°C, 3-o-ethyl ascorbic acid flexible body is added, the stirring speed is 200-500 rpm, and the stirring time is 5-10 min.

[0046] The beneficial technical effects of one or more of the above technical solutions are as follows:

[0047] This invention employs a phospholipid-free, cholesterol-free, and sorbitan-free flexible body system to achieve efficient encapsulation of 3-o-ethyl ascorbic acid. The average particle size of the flexible body is 152.6-243.5 nm, with a PDI < 0.25, exhibiting good stability and solving the problem of oxidative discoloration of 3-o-ethyl ascorbic acid.

[0048] The 3-o-ethyl ascorbic acid flexible body can increase the permeability of 3-o-ethyl ascorbic acid, improve the color change and stratification of the aqueous phase of the mask liquid, and increase its stability.

[0049] This invention provides an instant emulsified water-oil mask formulation for improving dull skin, comprising an aqueous phase component and an oil phase component. It also provides a method for preparing an instant emulsified water-oil mask liquid containing the above-mentioned water-oil formulation. The water and oil phases are mixed to form a uniform and stable emulsion. This preparation method is simple and easy to implement, and has low process cost.

[0050] The instant emulsified water-oil mask can significantly inhibit melanin synthesis, reduce lipofuscin deposition, and inhibit the generation of oxidation byproducts (ROS). Moringa seed oil and baobab seed oil in the formula can synergistically enhance the efficacy of active substances, increasing their inhibition rates against melanin, lipofuscin, and ROS to 89.9%, 75.5%, and 71.0%, respectively. This effectively reduces pigmentation, improves age-related age spots, enhances the skin's antioxidant capacity, and achieves radiant skin.

[0051] The present invention unexpectedly discovered that, in addition to the whitening and antioxidant effects mentioned above, the instant emulsified water-oil mask liquid also has a significant soothing effect. It can inhibit the expression of IL-6 in RAW264.7 cells, with an inhibition rate of 65.0%, enhance the skin's antioxidant capacity, and has a significant soothing effect. Attached Figure Description

[0052] The accompanying drawings, which form part of this invention, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an improper limitation of the invention.

[0053] Figure 1 Graphs showing the emulsification effects of different phase ratios;

[0054] Figure 2 The results of the stability study of the aqueous phase of the liquid for adding flexible face film;

[0055] Figure 3 Image showing the melanin content in the head of a zebrafish;

[0056] Figure 4 This is a graph showing the detection of lipofuscin content. Detailed Implementation

[0057] It should be noted that the following detailed description is illustrative and intended to provide further explanation of the invention. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0058] It should be noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the exemplary embodiments according to this application. As used herein, the singular form is intended to include the plural form as well, unless the context clearly indicates otherwise. Furthermore, it should be understood that when the terms "comprising" and / or "including" are used in this specification, they indicate the presence of features, steps, operations, devices, components, and / or combinations thereof.

[0059] The present invention will be further described below with reference to embodiments. The present invention will be further illustrated by way of embodiments, but this does not limit the present invention to the scope of the embodiments described. Unless otherwise specified, the test methods used in the embodiments and comparative examples are conventional methods; the materials and reagents used are commercially available unless otherwise specified; and the percentages mentioned in the embodiments and comparative examples are mass percentages unless otherwise specified.

[0060] Raw materials and their sources involved in the embodiments

[0061] Raw material name source Polyglycerol-2-isostearate (PG-2-IS) Shanghai Ronghai Biotechnology Co., Ltd. Polyglycerol-10 oleate (PG-10-O) Shanghai Ronghai Biotechnology Co., Ltd. 3-o-Ethyl Ascorbic Acid Shandong Freda Biotechnology Co., Ltd. Phenethyl resorcinol Qingdao Jiesiming Trading Co., Ltd. Moringa seed oil Koneo Trading (Shanghai) Co., Ltd. Baobab seed oil Guangzhou Aoxue Chemical Co., Ltd. AVC (Ammonium Acryloyldimethyltaurate / VP copolymer) Guangzhou Aoxue Chemical Co., Ltd. Sorbitol polyether-30 tetraisostearate Shanghai Gefeng Biotechnology Co., Ltd. Polyglycerol-6-didecanoate Shanghai Gefeng Biotechnology Co., Ltd.

[0062] Experimental Example 1

[0063] Flexible bodies were prepared according to the raw materials and component weights of Examples 1-3 and Comparative Examples 1-8 as shown in Table 1:

[0064] Table 1: Components and weights of 3-o-ethyl ascorbic acid flexible body

[0065]

[0066] The specific preparation methods of the flexible materials in Examples 1-7 and Comparative Examples 1-5 are as follows:

[0067] S1. Preparation of the oil phase: Polyglycerol-2 isostearate, β-sitosterol, and polyglycerol-10 oleate were placed in a sealed reaction vessel and dissolved in a chloroform-ethanol mixture at a volume ratio of 3:1. The amount of organic solvent used was 6 times the total mass of the oil phase. Under nitrogen sealing conditions, a slight positive pressure of 0.03 MPa was maintained, and the mixture was heated to 45°C and stirred until completely dissolved and mixed evenly to obtain the oil phase.

[0068] S2. Aqueous phase preparation: Dissolve 3-o-ethyl ascorbic acid in deionized water that has undergone vacuum degassing treatment. The vacuum degree of the vacuum degassing treatment is -0.09 MPa, the degassing time is 15 min, and the solution is heated to 45 °C to obtain the aqueous phase.

[0069] S3. Thin film formation: The oil phase obtained in S1 is placed in a rotary evaporation flask. The rotary evaporation temperature is 45°C, the vacuum degree is -0.07 MPa, and the rotation speed is 50 rpm. The rotary evaporation continues until no liquid droplets fall, forming a uniform thin film on the inner wall of the container.

[0070] S4. Thin film hydration: Add the aqueous phase obtained in S2 to the thin film obtained in S3, and perform rotational hydration under nitrogen protection. The rotational hydration temperature is 50°C, the rotation speed is 35 rpm, and the time is 50 min to obtain a flexible coarse dispersion.

[0071] S5. Particle size homogenization: The coarse dispersion of the flexible material obtained in S4 is cooled to 35°C, and then further cooled to 15°C in an ice-water bath. It is then transferred to a high-pressure homogenizer for high-pressure homogenization. The pressure of high-pressure homogenization is 800 bar, the number of cycles is 4, and the temperature of the homogenization process does not exceed 40°C, thus obtaining the flexible material.

[0072] The specific preparation method of liposomes in Comparative Example 6 is as follows:

[0073] S1. Preparation of the oil phase: Soybean lecithin, cholesterol, and Tween 80 are placed in a sealed reaction vessel and dissolved in an organic solvent chloroform-ethanol mixture at a volume ratio of 3:1. The amount of organic solvent used is 6 times the total mass of the oil phase. Under nitrogen sealing conditions, a slight positive pressure of 0.03 MPa is maintained, and the mixture is heated to 45°C and stirred until completely dissolved and mixed evenly to obtain the oil phase.

[0074] S2. Aqueous phase preparation: Dissolve 3-o-ethyl ascorbic acid in deionized water, degas at a vacuum degree of -0.09 MPa for 15 min, and heat to 45℃ to obtain the aqueous phase.

[0075] S3. Thin film formation: The oil phase obtained in S1 is placed in a rotary evaporation flask. The rotary evaporation temperature is 45℃, the vacuum degree is -0.07 MPa, and the rotation speed is 50 rpm. The rotary evaporation continues until the organic solvent is completely removed, forming a uniform thin film on the inner wall of the container.

[0076] S4. Thin film hydration: Add the aqueous phase obtained in S2 to the thin film obtained in S3, and perform rotational hydration under nitrogen protection. The rotational hydration temperature is 50℃, the rotation speed is 35 rpm, and the time is 50 min to obtain a coarse dispersion.

[0077] S5. Particle size homogenization: The flexible coarse dispersion obtained in S4 was cooled to 35°C, and then further cooled to 15°C in an ice-water bath. It was then transferred to a high-pressure homogenizer for high-pressure homogenization. The pressure of high-pressure homogenization was 800 bar, the number of cycles was 4, and the temperature of the homogenization process did not exceed 40°C, thus obtaining the liposomes of Comparative Example 6.

[0078] The specific preparation method of liposomes in Comparative Example 7 is as follows:

[0079] (1) Oil phase melting: Weigh polyglycerol-10 laurate, polyglycerol-6 oleate and sorbitan palmitate according to the above component ratio, place the above oil phase components in a sealed reaction vessel, heat to 75 ℃~85 ℃ under nitrogen protection, stir until completely melted and mixed evenly to obtain the oil phase;

[0080] (2) Aqueous phase preparation: 3-o-ethyl ascorbic acid was dissolved in deionized water that had been degassed under vacuum. The vacuum degree of the degassed water was -0.09 MPa and the degassed time was 15 min. The water was then heated to 45 °C to obtain the aqueous phase.

[0081] (3) Thin film formation: The oil phase obtained in step (1) is placed in a rotary evaporation flask. The rotary evaporation temperature is 45°C, the vacuum degree is -0.07 MPa, the rotation speed is 50 rpm, and the rotary evaporation continues until the organic solvent is completely removed, forming a uniform thin film on the inner wall of the container.

[0082] (4) Thin film hydration: Add the aqueous phase obtained in step (2) to the thin film obtained in step (3), and perform rotational hydration under nitrogen protection. The rotational hydration temperature is 50℃, the rotation speed is 35 rpm, and the time is 50 min to obtain a flexible coarse dispersion.

[0083] (5) Particle size homogenization: The flexible coarse dispersion obtained in step (4) is cooled to 35°C, and then further cooled to 15°C by an ice water bath. It is then transferred to a high-pressure homogenizer for high-pressure homogenization. The pressure of high-pressure homogenization is 800 bar, the number of cycles is 4, and the temperature of the homogenization process does not exceed 40°C, thus obtaining the flexible material of Comparative Example 7.

[0084] The following testing methods are applicable to all embodiments and comparative examples of the 3-o-ethyl ascorbic acid flexible body of the present invention. All tests were performed under the same conditions, and each test was repeated three times. The results are expressed as mean ± standard deviation.

[0085] 1. Determination of particle size and polydispersity index (PDI)

[0086] Dynamic light scattering (DLS) was used for particle size distribution: 0.1 mL of the flexible sample was diluted 100 times with 9.9 mL of purified water and gently shaken to avoid vigorous shaking. A Nano ZS laser particle size analyzer (Malvern, UK) was used for measurement. The measurement temperature was set to 25℃, the scattering angle to 173°, and the laser wavelength to 633 nm. Each sample was equilibrated for 120 s, and 12 consecutive measurements were taken, with the average value recorded. The instrument automatically output the average particle size (nm) and polydispersity index (PDI). PDI evaluation criteria: PDI < 0.2 indicates uniform particle size distribution, 0.2 ≤ PDI < 0.3 indicates a wide distribution, and PDI ≥ 0.3 indicates an uneven distribution.

[0087] 2. Measurement of Zeta potential

[0088] Laser Doppler Electrophoresis was used for determination: 0.1 mL of the flexible sample was diluted 100-fold with 9.9 mL of 10 mmol / L PBS buffer (pH 7.4). Measurements were performed using a Nano ZS Zeta potential analyzer (Malvern, UK). The measurement temperature was set to 25℃ and the electric field strength to 20 V / cm. Each sample was measured 15 times consecutively, and the average value was taken. The results are expressed in mV.

[0089] 3. Determination of 3-o-ethylascorbic acid encapsulation efficiency

[0090] The determination was performed using ultrafiltration centrifugation:

[0091] (1) Drawing the standard curve

[0092] Accurately weigh 10 mg of 3-o-ethyl ascorbic acid standard and place it in a 10 mL volumetric flask. Dissolve and dilute to the mark with purified water to obtain a 1.0 mg / mL standard stock solution. Take 0.05, 0.1, 0.2, 0.5, 1.0, and 2.0 mL of the standard stock solution, respectively, and dilute to 10 mL with purified water to obtain standard working solutions with concentrations of 5, 10, 20, 50, 100, and 200 μg / mL. Measure the peak area of ​​each concentration of standard working solution using high-performance liquid chromatography (HPLC). Perform linear regression of peak area (A) against concentration (C, μg / mL) to obtain the standard curve equation.

[0093] HPLC determination conditions: C18 column (4.6 mm × 250 mm, 5 μm); mobile phase: methanol:0.1% phosphoric acid aqueous solution = 15:85 (v / v); flow rate: 1.0 mL / min; detection wavelength: 254 nm; column temperature: 30℃; injection volume: 20 μL.

[0094] (2) Determination of total drug content

[0095] Take 0.1 mL of the flexible sample, add 0.9 mL of methanol, vortex for 3 min to destroy the vesicle structure, then add 0.5 mL of purified water, centrifuge at 12000 rpm for 10 min, take the supernatant and filter it through a 0.22 μm microporous membrane before HPLC determination, and calculate the total drug content (Wtotal) according to the standard curve.

[0096] (3) Determination of free drug content

[0097] Take 0.5 mL of the flexible sample and place it in an ultrafiltration centrifuge tube with a molecular weight cutoff of 10 kDa. Centrifuge at 12,000 rpm for 30 min and collect the filtrate. Take 0.1 mL of the filtrate, dilute it with purified water to an appropriate concentration, and then perform HPLC analysis. Calculate the free drug content (Wfree) based on the standard curve.

[0098] (4) Encapsulation ratio calculation

[0099] Encapsulation rate (%) = (Wtotal - Wfree) / Wtotal * 100%

[0100] 4. Measurement of color change and color difference value (ΔE*)

[0101] The Lab color value of the sample was measured using a spectrophotometer, and the total color difference ΔE was calculated.

[0102] Take 2 mL of the flexible sample and place it in a transparent quartz cuvette (optical path 1 cm). Measure the L, a, and b values ​​of the sample using a CM-5 spectrophotometer (Konica Minolta, Japan). Use purified water as a standard white plate (L=100, a*=0, b*=0) for calibration. Measure each sample three times and take the average value.

[0103] Wherein, L0, a0, and b0 are the measured values ​​immediately after preparation (0 days), and L, a, and b are the measured values ​​after the accelerated stability test at 40°C.

[0104] ΔE evaluation criteria: ΔE* < 2.0 indicates almost no color / no obvious change, 2.0 ≤ ΔE* < 5.0 indicates slight color change (slight yellow to light yellow), 5.0 ≤ ΔE* < 10.0 indicates obvious color change (yellow), and ΔE* ≥ 10.0 indicates severe color change (dark yellow to brownish yellow).

[0105] 5. Determination of 3-o-ethylascorbic acid retention rate

[0106] The content of 3-o-ethyl ascorbic acid in the samples before and after the accelerated stability test at 40°C was determined by HPLC, and the retention rate was calculated.

[0107] (1) Initial content determination

[0108] Take the flexible sample immediately after preparation and determine the initial total drug content (C0) according to the method of "Determination of 3-o-ethyl ascorbic acid encapsulation rate" under "Determination of total drug content".

[0109] (2) Determination of content after acceleration

[0110] The flexible sample was sealed and placed in a 40°C incubator for 7 days for acceleration. The accelerated sample was then taken and the total drug content (C7) was determined using the same method as described above.

[0111] (3) Calculation of retention rate

[0112] 3-O-Ethyl Ascorbic Acid Retention Rate (%) = C7 / C0 * 100%

[0113] 6. Determination of the permeability of a 0.22 μm filter membrane

[0114] The flexible deformation capability of flexible materials is evaluated using the membrane extrusion method.

[0115] Take 1.0 mL of the flexible sample and slowly pass it through a 0.22 μm pore size polycarbonate track-etched membrane (Whatman, UK). Collect the extruded liquid and determine the particle size distribution using a Nano ZS laser particle size analyzer. Calculate the membrane throughput: 0.22 μm membrane throughput (%) = mout / min * 100%

[0116] Wherein, min is the total mass of the flexible bodies in the sample before extrusion (converted by measuring the total lipid concentration), and mout is the total mass of the flexible bodies in the collected liquid after extrusion. The operation was carried out under constant temperature conditions of 25℃, with manual extrusion and the extrusion speed controlled at approximately 1 mL / min.

[0117] A pass rate >80% indicates that the flexible material has excellent flexibility and can pass through skin gaps smaller than its own particle size; a pass rate of 50%~80% indicates that the flexibility is average; a pass rate <50% indicates that the flexible material is relatively rigid and difficult to deform and penetrate.

[0118] 7.40°C Accelerated Stability Testing Method

[0119] The flexible body was dispensed into transparent glass sample vials, sealed, and continuously examined at room temperature and 40±2℃ for 3 months.

[0120] Evaluation indicators: Color change index ΔE* < 5.0 is acceptable; Particle size increase of <20% from day 0 over 3 months indicates stable particle size; 3-o-ethyl ascorbic acid retention rate >80% is excellent, 60%~80% is good, and <60% is poor; 0.22 μm filter membrane throughput decrease of <10% indicates stable flexibility.

[0121] Table 2 Characterization indicators and stability test results of flexible body preparation

[0122]

[0123] The polyglycerol ester 3-o-ethyl ascorbic acid flexible body described in this invention exhibits uniform particle size (152.6-243.5 nm, PDI < 0.25) and 3-o-ethyl ascorbic acid encapsulation efficiency of 86.7% under phospholipid-free, cholesterol-free, and sorbitan-free conditions, with a stable zeta potential between -31 and -36. The 0.22μm filter membrane had a throughput of >59%, with the throughput of Examples 1-2 consistently above 86%, demonstrating excellent flexibility and deformability. Under accelerated testing conditions at 40°C for 3 months, the retention rate of 3-o-ethyl ascorbic acid was above 69.2%, with the retention rate of Examples 1-2 consistently above 92.8%, and no significant color change (ΔE*<2), which was significantly better than traditional phospholipid systems and other polyglycerol ester compound systems (Comparative Examples 6-7). Meanwhile, when the ratio of PG-2-IS, β-sitosterol and PG-10-O deviated from the range of this invention (Comparative Examples 1–5), the particle size increased significantly or the PDI deteriorated, and the encapsulation efficiency and stability decreased significantly, proving that the polyglycerol ester composition and ratio described in this invention are the optimal selection (Table 2).

[0124] Experimental Example 2

[0125] Prepare the facial mask liquid according to the weight comparison of raw materials and components shown in Table 3:

[0126] Table 3. Mask Liquid Preparation Formula and Amounts of Each Component

[0127]

[0128] The specific preparation method for this facial mask liquid is as follows:

[0129] (1) Preparation of aqueous phase: Weigh out polyol, 0.3% AVC, 0.05% EDTA 2Na and water according to the component ratio shown in Table 3, mix and heat to 80°C, stir until completely dissolved and mixed evenly; then cool down to 70°C, add 0.5% p-hydroxyacetophenone and 0.5% 1,2-hexanediol, continue to cool down to 40°C, add 3-o-ethyl ascorbic acid flexible body according to the group content in Table 3, stir at 300 rpm for 8 min until mixed evenly to obtain aqueous phase;

[0130] (2) Preparation of oil phase: Weigh dioctyl carbonate according to the component ratio shown in Table 3, heat to 42°C, add phenylethyl resorcinol, moringa seed oil and baobab seed oil, stir at 300 rpm for 12 min until completely dissolved, then cool to room temperature, add sorbitol polyether-30 tetraisostearate and polyglycerol-6 didecanoate (mass ratio of the two is 3:2), stir and mix evenly to obtain the oil phase;

[0131] (3) Phase emulsification: Mix the aqueous phase and the oil phase evenly according to the corresponding mass ratio to obtain an instant emulsified water-oil mask liquid.

[0132] The following testing methods are applicable to the embodiments and comparative examples described in this invention. All tests are performed under the same conditions, and each test is repeated three times. The results are expressed as mean ± standard deviation.

[0133] 1. Determination of instant emulsification time

[0134] A measured amount of the aqueous phase was placed in a transparent glass container and equilibrated in a constant temperature water bath at 25±1℃ for 10 min. The oil phase was poured onto the surface of the aqueous phase in a thin, uniform stream while simultaneously starting a stopwatch. Magnetic stirring was activated at 100 rpm, and the mixing state of the oil and water phases was observed. When the system appeared uniformly milky white to the naked eye, with no visible oil droplets or oil-water boundary, this moment was recorded as the instantaneous emulsification time, measured in seconds (s). Each group was measured in triplicate, and the average value was taken.

[0135] 2.24 h static stratification observation

[0136] The emulsified facial mask liquid was transferred to a transparent stoppered glass graduated cylinder, sealed, and allowed to stand at a constant temperature of 25±1℃ for 24 hours. Two or more trained personnel visually observed and recorded the phenomena under incandescent light. The following criteria were defined: "No stratification": a homogeneous milky white or semi-transparent system with no visible supernatant layer, bottom sediment, or oil phase precipitation; "Slight stratification": a very thin transparent or semi-transparent layer at the bottom (height < 5% of total liquid column), which could be restored to homogeneity with gentle shaking; "Significant stratification": obvious sedimentation at the bottom or an oil phase layer at the top (height ≥ 5% of total liquid column), requiring external stirring to restore homogeneity; "Severe stratification": complete separation of oil and water into two phases that could not be restored to homogeneity by simple shaking.

[0137] 3. Franz diffusion cell transdermal permeation experiment

[0138] A modified Franz vertical diffusion cell with an effective diffusion area of ​​1.77 cm² and a receiving cell volume of 7.0 mL was used. Isolated rat abdominal skin (1.0–1.5 mm thick, stratum corneum facing upwards) was fixed between the supply and receiving cells. The receiving solution was PBS (pH 7.4) with a solubilizer, and the mixture was kept in a constant temperature water bath at 32±0.5℃ with stirring at 600 rpm. After the skin reached hydration equilibration for 30 min, a mask solution sample of 200 mg / cm² was applied to the supply cell. Samples of 0.5 mL were taken at 1, 2, 4, 6, 8, 12, and 24 h (with immediate replenishment of isothermal and equal-volume fresh receiving solution). The concentration of the active ingredient was determined by HPLC. The permeability was calculated based on the cumulative permeation over 24 hours using the following formula: Permeability (%) = Q²⁴ / D * 100%, where D is the dosage (μg / cm²), i.e., the amount applied (200 mg / cm²) × the percentage of the active ingredient in the sample.

[0139] 4. The methods for determining particle size and polydispersity index (PDI) are the same as in Experimental Example 1.

[0140] Table 4. Results of test on stability and permeability of the facial mask liquid

[0141]

[0142] The test results are shown in Table 4:

[0143] As can be seen from Application Examples 1-4, the flexible body prepared by the present invention can effectively promote the penetration and absorption of 3-o-ethyl ascorbic acid and reduce the particle size of the liquid. Application Example 3 has the shortest emulsification time and is stable under 24-hour standing conditions, so it is the optimal application example.

[0144] As can be seen from Application Examples 1-4 and Application Comparative Example 5, adding an appropriate amount of Moringa seed oil increases the permeability of 3-o-ethyl ascorbic acid and phenylethyl resorcinol. Therefore, adding Moringa seed oil can increase the permeation and absorption of active ingredients.

[0145] As can be seen from Application Examples 1-4 and Application Comparative Examples 5-6, the addition of baobab seed oil can further enhance the effect of moringa seed oil on promoting the penetration and absorption of active ingredients, thus playing a synergistic role. In Application Example 3, the penetration rate of 3-o-ethyl ascorbic acid increased from 21.3% (Application Comparative Example 6) to 84.9%, and the penetration rate of phenylethyl resorcinol increased from 18.5% (Application Comparative Example 6) to 69.5%, both of which were better than the penetration rates when added alone.

[0146] As can be seen from Application Examples 1-4 and Comparative Example 7, when the phase ratio is 18:10, stratification occurs after standing for 24 hours, and the emulsification time is extended to 31.6 seconds. This indicates that 25:3 is the optimal emulsification ratio for this instant emulsifying mask. Figure 1 ).

[0147] As can be seen from Application Examples 1-4 and Application Comparative Examples 1-2, erythritol can reduce the particle size of the liquid, with a particle size of only 292±24nm. Compared with the addition of erythritol at a lower concentration (Application Comparative Example 1) and other polyols added in equal amounts, the particle size is the lowest and the PDI is the best. Therefore, Application Example 3 is the best example.

[0148] Experimental Example 3

[0149] Method for 3-month stability study of aqueous phase of facial mask liquid: Prepare aqueous phase of facial mask liquid according to the groups in Table 3. Dispense the prepared aqueous phase of facial mask liquid into transparent sample bottles, seal them, and place them at room temperature, 45±2℃ and -18±2℃ respectively for 3 consecutive months. Record the stability study results.

[0150] Table 5 Results of the aqueous phase stability study of the facial mask liquid

[0151]

[0152] As shown in Application Examples 1-4 and Comparative Examples 1 and 3, the appearance and color of the aqueous phase of the mask liquid in Application Examples 1-4 were normal. Without the addition of the flexible agent (Comparative Example 3), the aqueous phase of the mask liquid showed slight yellowing at room temperature and severe yellowing at 45°C; with the addition of the flexible agent (Application Examples 1-4), the aqueous phase of the mask liquid was normal. This indicates that the addition of the flexible agent can also improve the color change of other raw materials and maintain the stability of the aqueous phase. Figure 2 However, the high-concentration flexible material (using Comparative Example 1) delaminated under all three testing conditions, and its color turned severely yellow at 45°C, and also slightly yellowed at room temperature and -18°C. Therefore, it is indicated that the addition amount in Examples 1-4 is optimal.

[0153] Test Example 4

[0154] Prepare the mask liquid according to Table 3, and use it for melanin content detection after preparation. The whitening efficacy test method for zebrafish was adopted (referring to "T / ZHCA 012-2021 Test Method for Whitening Efficacy of Zebrafish Embryo Melanin Inhibition"). Fifteen wild-type AB strain zebrafish, fertilized for 6 hours, were added to each well of a 6-well plate. A normal control group, a sample group, and a positive control group were set up. The sample group was added with 0.5% facial mask liquid, and the positive control group was added with 0.3% arbutin. After incubation at 28℃ in the dark for 45 hours, ten zebrafish from each group were randomly selected and photographed under a dissecting microscope. Advanced image processing software was used to analyze and collect data. The melanin signal intensity (S) in the zebrafish head was analyzed. The whitening efficacy (%) was calculated using the following formula: Whitening efficacy (%) = [S(normal control group) - S(sample group)] / S(normal control group) * 100%. The whitening efficacy of the sample was then calculated and determined. Compared with the normal control group, *: p < 0.05, **: p < 0.01, ***: p < 0.001.

[0155] Table 6 Results of melanin content detection in zebrafish heads

[0156]

[0157] The results are shown in Table 6 and Figure 3 As shown in Application Examples 1-4 and Comparative Examples 5-6, the inhibition rates of melanin by adding baobab seed oil alone (Comparative Example 5) or moringa seed oil alone (Comparative Example 6) were 43.4% and 52%, respectively. However, when both were added simultaneously (Application Example 3), the inhibition rate of melanin reached 89.9%, which is close to the inhibition effect of arbutin, indicating that the two have a significant synergistic effect.

[0158] Experimental Example 5

[0159] The mask liquid was prepared according to Table 3. After preparation, the accumulation of lipofuscin was detected using the Schmorl method with a keratinocyte model under H2O2 (0.25mM) stimulation. HaCaT cells were cultured in 6-well plates. A normal control group, a negative control group, a sample group, and a positive control group were set up. The normal control group was cultured in High Glu DMEM medium, while the other groups were stimulated with H2O2 (0.25 mM). Subsequently, the negative control group was cultured in High Glu DMEM medium. The sample group had 0.02% mask solution added to High Glu DMEM medium, and the positive control group had 300 nM quercetin added. After incubation at 37℃ and 5% CO2 for 24 h, the accumulation of lipofuscin was detected using the Schmorl method. The inhibition rate was calculated as [IOD(negative control group) - IOD(sample group)] / [IOD(negative control group)] * 100%. Compared with the normal control group, *: p < 0.05, **: p < 0.01, ***: p < 0.001; compared with the negative control group, #: p < 0.05, ##: p < 0.01, ###: p < 0.001.

[0160] Table 7. Detection values ​​of lipofuscin content

[0161]

[0162] The results are shown in Table 7 and Figure 4 As shown:

[0163] As shown in Application Examples 1-4 and Comparative Examples 5-6, the inhibition rates of baobab seed oil alone (Comparative Example 5) or with the addition of moringa seed oil (Comparative Example 6) on lipofuscin were 50.7% and 49.6%, respectively. However, when both were added simultaneously (Application Example 3), the inhibition rate of lipofuscin was as high as 75.5%, which was better than that of moringa seed oil and baobab seed oil alone in Application Examples 5-6, and also better than the inhibition effect of 300 nM quercetin. This indicates that the two have a significant synergistic effect.

[0164] Experimental Example 6

[0165] The mask solution was prepared according to Table 3. After preparation, the scavenging effect of the mask solution on the oxidation byproduct ROS of zebrafish was tested. Fifteen melanin allele mutant zebrafish (Albino) were added to each well of a 6-well plate. Normal control, negative control, sample group, and positive control groups were set up. Except for the normal control group, the other groups used 1.5 μM menadione solution to establish a zebrafish oxidative stress model. The negative control group was incubated at 28℃ in the dark for 22 h. The sample group was added with 0.01% of the mask solution, and the positive control group was added with 15.6 μg / ml NAC (N-acetylcysteine). All groups were incubated at 28℃ in the dark for 22 h, and then... CellROX® fluorescent reagent was used for staining, and the fluorescence intensity A of the zebrafish yolk sac was analyzed. The antioxidant efficacy (%) was calculated and determined according to the following formula: Antioxidant efficacy (%) = [A(negative control group) - A(sample group)] / [A(negative control group)] * 100%. The antioxidant efficacy of the sample was then calculated and determined. Compared with the normal control group, *: p < 0.05, **: p < 0.01, ***: p < 0.001; compared with the negative control group, #: p < 0.05, ##: p < 0.01, ###: p < 0.001.

[0166] Table 8. Fluorescence intensity values ​​of zebrafish yolk sacs

[0167]

[0168] The results are shown in Table 8:

[0169] As shown in Application Examples 1-4 and Comparative Examples 5-6, the inhibition rates of baobab seed oil alone (Comparative Example 5) or with the addition of moringa seed oil (Comparative Example 6) on the oxidation byproduct ROS were 51.0% and 50.4%, respectively. When both were added simultaneously (Application Example 3), the inhibition rate of ROS was as high as 71.0%, which is better than the inhibition rate of adding moringa seed oil and baobab seed oil alone in Application Examples 5-6, and also better than the inhibition effect of the NAC group. This shows that the two have a significant synergistic effect.

[0170] Experimental Example 7

[0171] The mask solution was prepared according to Table 3. After preparation, the inhibitory effect of the mask solution on the inflammatory factor IL-6 in mouse macrophage RAW264.7 cells was tested. RAW264.7 cells were seeded at a density of 1×10⁶ cells / well in 6-well plates and cultured in DMEM high-glucose medium containing 10% fetal bovine serum (FBS) at 37°C and 5% CO₂ for 24 h to allow them to adhere. Normal control, negative control, sample group, and positive control were set up. Except for the normal control group, the other groups used 1 μg / mL LPS solution to establish an inflammation model. The normal control group was replaced with fresh medium. The sample group was added with 0.01% of the mask solution (diluted with serum-free medium), and the positive control group was added with 50 μg / mL dexamethasone. All groups were incubated at 37°C and 5% CO₂ for 24 h. After incubation, the cell culture supernatant of each well was collected, and the IL-6 content was detected according to the instructions of the mouse IL-6 ELISA kit.

[0172] The soothing effect is calculated using the following formula:

[0173] Soothing efficacy (%) = [A(negative control group) - A(sample group)] / [A(negative control group)] × 100%

[0174] Compared with the normal control group, *: p<0.05, **: p<0.01, ***: p<0.001; compared with the negative control group, #: p<0.05, ##: p<0.01, ###: p<0.001.

[0175] Table 9. Detection of IL-6 content in mouse RAW264.7 cells

[0176]

[0177] The results are shown in Table 9. Compared with the normal control group, the IL-6 content in the negative control group was significantly upregulated after stimulation with 1 μg / mL LPS (p<0.001). After treatment with the mask liquid prepared in this invention, the expression and release of IL-6 can be effectively inhibited, and it has a significant soothing effect.

[0178] As shown in Application Examples 1-4 and Comparative Examples 5-6, the inhibition rates of IL-6 by baobab seed oil alone (Comparative Example 5) or by adding moringa seed oil (Comparative Example 6) were 41.6% and 43.0%, respectively. However, when both were added simultaneously (Application Example 3), the inhibition rate of IL-6 was as high as 65.0%, which was better than the cases in Application Examples 5-6 where moringa seed oil and baobab seed oil were added alone. This indicates that the two have a significant synergistic effect.

Claims

1. A composition for improving skin dullness, characterized by, It includes the following components: 3-o-ethyl ascorbic acid flexible body, phenylethyl resorcinol, moringa seed oil and baobab seed oil.

2. The composition for improving dull skin according to claim 1, characterized in that, The 3-o-ethyl ascorbic acid flexible body comprises the following components in the indicated mass fractions: 1-8 parts of 3-o-ethyl ascorbic acid, 1-18 parts of polyglycerol-2 isostearate, 1-18 parts of β-sitosterol, 1-10 parts of polyglycerol-10 oleate, and water to a total of 100 parts. The mass ratio of polyglycerol-2 isostearate, β-sitosterol, and polyglycerol-10 oleate is (35~45):(35~45):(15~25); preferably, 3-o-ethyl ascorbic acid 3-5 parts, polyglycerol-2 isostearate 14-18 parts, β-sitosterol 14-18 parts, and polyglycerol-10 oleate 6-10 parts; the mass ratio of polyglycerol-2 isostearate, β-sitosterol, and polyglycerol-10 oleate is 40:40:

20.

3. The composition for improving dull skin according to claim 2, characterized in that, The preparation method of the 3-o-ethyl ascorbic acid flexible body is as follows: S1. Preparation of oil phase: Polyglycerol-2 isostearate, β-sitosterol and polyglycerol-10 oleate are placed in a closed reaction vessel, dissolved in an organic solvent, heated to 40~50°C under inert gas protection, and stirred until completely dissolved and mixed evenly to obtain the oil phase; S2. Preparation of aqueous phase: Dissolve 3-o-ethyl ascorbic acid in deionized water that has been degassed under vacuum, and heat to 40–50 °C to obtain the aqueous phase; S3. Thin film formation: The oil phase obtained in S1 is placed in a rotary evaporation flask and rotary evaporated until no liquid drops fall, forming a uniform thin film on the inner wall of the container; S4. Thin film hydration: Add the aqueous phase obtained in S2 to the thin film obtained in S3, and perform rotational hydration under inert gas protection to obtain a flexible coarse dispersion; S5. Particle size homogenization: The coarse dispersion of the flexible body obtained in S4 is cooled to 30°C~40°C, and then further cooled to 10~20°C in an ice-water bath. High-pressure homogenization or high-pressure shear homogenization is then performed to obtain a flexible body with an average particle size of 150–250 nm and PDI < 0.

25.

4. The composition for improving dull skin according to claim 3, characterized in that, In S1, the inert gas is one of nitrogen, argon or carbon dioxide, preferably nitrogen; Inert gas protection is used to maintain a slight positive pressure of nitrogen or nitrogen sealing, wherein the slight positive pressure is 0.01 MPa to 0.05 MPa; The organic solvent is selected from one or more of chloroform, ethanol, methanol, and diethyl ether, preferably a chloroform-ethanol mixed solvent with a volume ratio of 2:1 to 4:

1. The amount of organic solvent used is 4-10 times the total mass of the oil phase, preferably 6 times; In S2, the vacuum degree of the vacuum degassing process is -0.08 MPa to -0.10 MPa, and the degassing time is 10–20 min. In step S3, the rotary evaporation temperature is 40°C~50°C, the vacuum degree is -0.06 MPa~-0.08 MPa, and the rotation speed is 40 rpm~60 rpm. In step S4, the temperature for rotational hydration is 40°C to 50°C, the rotation speed is 30 rpm to 40 rpm, and the time is 30 min to 60 min. In S5, the pressure of high-pressure homogenization is 600–1000 bar, the number of cycles is 3–5, and the temperature of the homogenization process does not exceed 40°C. The high-pressure shear homogenization is performed at a rotation speed of 10,000 rpm to 20,000 rpm for 5 min to 15 min; the homogenization process temperature does not exceed 40°C.

5. A facial mask liquid comprising the composition of claim 1 or 2, said facial mask liquid comprising an aqueous phase and an oil phase, characterized in that, The aqueous and oil phases, by mass, comprise the following components: The aqueous phase includes 1-20 parts of 3-o-ethyl ascorbic acid flexible body, 2-10 parts of polyol, 0.01-2 parts of rheology modifier, 0.01-0.1 parts of chelating agent, 0.01-1 parts of preservative, and water to make up to 100 parts. The oil phase includes 0.1-5 parts of moringa seed oil, 0.1-15 parts of baobab seed oil, 0.1-0.5 parts of phenylethyl resorcinol, 0.1-8 parts of sorbitol polyether-30 tetraisostearate, and 0.1-6 parts of polyglycerol-6 didecanoate, with liquid oils added to bring the total to 100 parts.

6. A facial mask liquid according to claim 5, wherein the facial mask liquid comprises an aqueous phase and an oil phase, characterized in that, The aqueous and oil phases, by mass, comprise the following components: The aqueous phase includes 5-10 parts of 3-o-ethyl ascorbic acid flexible body, 4-6 parts of polyol, 0.01-0.5 parts of rheology modifier, 0.01-0.05 parts of chelating agent, 0.5-1 parts of preservative, and water to make up to 100 parts. The oil phase includes 2-3 parts moringa seed oil, 5-10 parts baobab seed oil, 0.1-0.5 parts phenylethyl resorcinol, 0.1-6 parts sorbitol polyether-30 tetraisostearate, 0.1-4 parts polyglycerol-6 didecanoate, and liquid oils to make up to 100 parts.

7. A facial mask liquid according to claim 5, characterized in that, The mass ratio of the aqueous phase to the oil phase is (25–18):(1–10), preferably 25:3; The mass ratio of sorbitol polyether-30 tetraisostearate to polyglycerol-6 didecanoate is 3:

2.

8. A facial mask liquid according to claim 5, characterized in that, The polyol is any one or both of erythritol and xylitol; The rheology modifier is one or more of xanthan gum, carbomer, hydroxyethyl cellulose, hydrolyzed sclerotium gum, and ammonium acryloyldimethyl taurate / VP copolymer; The chelating agent is one or more of EDTA-2Na and EDTA-4Na; The preservative is one or more of p-hydroxyacetophenone and 1,2-hexanediol; The liquid oil is one or more of the following: dioctyl carbonate, caprylic / capric triglyceride, isohexadecane, isopropyl myristate, isononyl isononanoate, and triglyceride (ethylhexanoate).

9. A facial mask liquid according to claim 5, characterized in that, Its preparation method includes the following steps: S1: Aqueous phase preparation: Polyol, rheology modifier, chelating agent and water are mixed and heated to 75–85 °C, stirred until completely dissolved and mixed evenly; then cooled down, preservative and 3-o-ethyl ascorbic acid flexible body are added, stirred and mixed evenly to obtain the aqueous phase; S2: Oil phase preparation: (1) Heat the liquid oil to 40~45°C, add phenylethyl resorcinol, moringa seed oil and baobab seed oil, stir for 10–15 min until completely dissolved, and cool to room temperature; (2) Add sorbitol polyether-30 tetraisostearate and polyglycerol-6 didecanoate to (1), stir and mix evenly to obtain the oil phase; S3: Phase Emulsification: Cool the aqueous phase obtained from S1 to room temperature and mix it evenly with the oil phase obtained from S2 to obtain an instant emulsified water-oil facial mask liquid.

10. A facial mask liquid according to claim 8, characterized in that, In step S1, the temperature is cooled to 65–75°C, a preservative is added, the temperature is cooled to 35–45°C, 3-o-ethyl ascorbic acid flexible body is added, the stirring speed is 200–500 rpm, and the stirring time is 5–10 min.

Images